Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis.

Area of Science:

• Oncology
• Molecular Biology
• Hepatology

Background:

• MicroRNA 21 (miR-21) is upregulated in many cancers and considered an oncogene.
• Its role in driving liver cancer (hepatocellular carcinoma, HCC) in vivo is not well understood.
• Previous studies suggest miR-21 promotes liver steatosis and inflammation.

Purpose of the Study:

• To investigate the in vivo role of miR-21 in hepatocarcinogenesis.
• To determine if miR-21 deficiency promotes or inhibits liver tumor development.

Main Methods:

• Used diethylnitrosamine (DEN)-induced and PTEN-deficient mouse models of HCC.
• Generated mice with total or hepatocyte-specific genetic deletion of miR-21.
• Performed gene and protein expression analyses on liver tissues.

Main Results:

• miR-21 deficiency, in both models, fostered HCC development, contradicting its expected oncogenic role.
• Lack of miR-21 increased expression of oncogenes like Cdc25a.
• Observed subtle pathway deregulations (MAPK, HiPPO, STAT3) and altered anti-tumoral immune responses.

Conclusions:

• miR-21 deficiency promotes a pro-tumoral microenvironment, leading to HCC development through complex mechanisms.
• These findings challenge the established view of miR-21 as a potent oncomiR in the liver.
• Caution is advised when considering miR-21 inhibition as a therapeutic strategy for HCC.